# Federal Register #2026-22339

NHLBI patent-license opportunity for catheter-based intramyocardial ablation technology

**Buyer:** National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services
**Posted:** November 02, 2026
**Respond By:** December 02, 2026
**Identifier:** 2026-22339
**NAICS:** 334510

The National Heart, Lung, and Blood Institute is considering an exclusive patent license for technologies targeting ventricular arrhythmia treatment.

### Description

The National Heart, Lung and Blood Institute (NHLBI) is contemplating an exclusive, royalty-bearing patent license to AntaraCore Systems, Inc. for inventions in two patent estates. The license may cover a worldwide territory and a field of use limited to catheter-based intramyocardial ablation for treating ventricular arrhythmia in a human. The inventions include a catheter-based system for accessing and ablating hard-to-reach tissue within the ventricular wall, and a pacing system intended to improve cardiac resynchronization therapy. Written comments and license applications received by NHLBI by December 2, 2026, will be considered.

[View original listing](https://www.federalregister.gov/documents/2026/11/02/2026-22339/prospective-grant-of-exclusive-patent-license-catheter-based-intramyocardial-ablation-for-treating)